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1. Introduction 
The development of acute ethanol-induced fatty 
liver is associated with a marked increase in the activity 
of the cytoplasmic phosphatidate phosphohydrolase 
(EC 3 .1.3.4) in the liver [ 1,2], but the mechanism by 
which ethanol administration stimulates the activity 
of this enzyme is not known. 
It is well established that an intact pituitary gland 
and adrenal cortex are necessary for the production 
of acute ethanol-induced fatty liver [3-51, but the 
hormones involved in this process have not been 
identified, although ethanol is known to influence the 
plasma concentrations of several hormones [6-91. 
The present study investigates the effects on hepatic 
soluble phosphatidate phosphohydrolase of selected 
hormones which could be anticipated to be involved 
in the development of ethanol-induced fatty liver. 
The activity of phosphatidate phosphohydrolase in 
ratliver increased significantly after in vivo administra- 
tion of somatotropin (growth hormone), cortico- 
tropin-( 1-24)tetracosapeptide and cortisol. A 3-fold 
increase in the enzyme activity in perfused liver indi- 
cated that cortisol acts directly on the liver cells, prob- 
ably by increasing the synthesis of enzyme protein. 
2. Materials and methods 
2.1. Hormones and reagents 
Corticotropin-jl-24)tetracosapeptide (Synacthen, 
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a synthetic polypeptide possessing adrenocortico- 
tropic activity) was purchased from Ciba-Geigy 
(Basel), insulin (Actrapid) from Novo Industri 
(Copenhagen), and other hormones from Sigma 
Chemical Co. (St Louis, MO). L-Thyroxine was dis- 
solved in 0.1 M NaOH and adjusted to pH 10 with 
HCl. Glucagon (1 mg/ml) was dissolved in 10 mM 
HCl and diluted to 0.5 mg/ml with 0.25 M sodium 
phosphate (pH 7.4) just before injection. Somato- 
tropin (growth hormone) was dissolved in 0.04 M 
acetic acid and other hormones in 0.15 M NaCl. 
Phosphatidic acid (disodium salt, prepared from 
egg phosphatidylcholine) was obtained from Koch- 
Light Labs (Colnbrook, Bucks), and Eagle’s modified 
minimum essential medium (Auto-Pow 1 l-l 10 with 
Earle’s salts) from Flow Labs (Irvine). 
2.2. In vivo experiments 
Fed male Sprague-Dawley rats (240-400 g) were 
used. One group of rats was injected with each of the 
hormones shown in table 1. The control rats received 
an equal amount of the appropriate vehicle (1 ml/kg 
body wt). After 4 h the rats were anaesthetized with 
pentobarbital(60 mg/kg body wt) and a piece of liver 
was taken, rinsed with saline, blotted and prepared 
for the determination of soluble phosphatidate phos- 
phohydrolase activity as in [ 11. 
2.3. Perfusion experiments 
Each rat was anaesthetized with pentobarbital and 
the portal vein and the inferior vena cava cannulated. 
Perfusion was started immediately with Krebs-Ringer 
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bicarbonate solution in equilibrium with 0z/C02 
(19: 1). The liver was removed and perfusion con- 
tinued at 35°C in a recirculating system incorporating 
a membrane oxygenator [lo] constructed from 5 m 
Dow Corning silastic tubing (type 602-235), 1.47 mm 
i.d. and 0.24 mm wall thickness. The perfusate flow 
was 3 ml . min-’ . g liver-‘, and the oxygenator was 
able to maintain the arterial oxygen at 0.81 mM as 
measured with an oxygen electrode during the 
perfusion. The oxygen consumption was 
2.06 pmol _ min-’ . g liver-‘, which is in accordance 
with data on perfusions with hemoglobin-free [ 1 l] 
and erythrocyte-containing [ 121 media. Eagle’s 
minimum essential medium (70 ml) was used as the 
perfusion fluid, supplemented with 1.8 mmol NaHCOs, 
0.14 mmol glutamine, 3500 units penicillin G and 
3.5 mg streptomycin sulphate. Five mg cortisol-21- 
succinate (sodium salt), 70 pg actinomycin D or 
70 mU insulin were added where indicated. In the 
perfusions with insulin, further insulin was infused 
into the perfusion medium at a rate of 0.5 mu. min-r . 
2.4. Assay of phosphatidatephosphohydrolase activity 
The activity of the cytoplasmic phosphatidate 
phosphohydrolase was determined using an aqueous 
dispersion of phosphatidate as the substrate [ 11, 
except that 0.2 mM EGTA [ethyleneglycol-bis- 
@-aminoethyl ether)NJ’-tetracetic acid] was included 
in the incubation medium [ 131. Protein was deter- 
mined by the biuret method [ 141. 
3. Results and discussion 
A single intraperitoneal injection of a saline 
pituitary homogenate equivalent to a whole rat 
pituitary gland [3] increased the activity of the 
hepatic phosphatidate phosphohydrolase in prelim- 
inary experiments by more than 2-fold (data not 
shown). Since this injection is also capable of causing 
fat accumulation in the liver [3], the effects of those 
pituitary hormones, the secretion of which is influ- 
enced by the administration of ethanol were investi- 
gated in vivo (table 1). Somatotropin and corticotropin 
increased the activity of hepatic phosphatidate phos- 
phohydrolase by 66% and 43%, respectively, whereas 
vasopressin was without effect. A dose of 10 U vaso- 
pressin/kg body wt was needed to cause a significant 
increase in the phosphatidate phosphohydrolase, but 
the physical signs observed in the rat indicated that 
this was probably secondary to some toxic effect. 
Since the effect of corticotropin could be expected 
to be due to the release of adrenal corticosteroids, 
the effects of cortisol were also ascertained. Cortisol 
Table 1 
Activity of soluble phosphatidate phosphohydrolase in rat liver 4 h after an intraperitoneal 
injection of hormone 
Hormone Dose Soluble phosphatidate phosphohydrolase Change 
(kg body wt-‘) activity (nmol. s-’ . g wet wt-‘) 
Hormone-treated rats Control rats 
Somatotropin 2 u 4.52 + 0.27 (6) 2.73 * 0.31 (6) 66%b 
Corticotropina 25 u 4.69 * 0.40 (6) 3.53 f 0.32 (6) 43%b 
Vasopressin 2.5 u 3.78 f 0.33 (6) 3.28 * 0.35 (6) 
Cortisol 5 mg 5.56 + 0.30 (7) 2.95 f 0.41 (7) fl&c 
Thyroxine 5 mg 3.42 + 0.52 (4) 3.59 f 0.45 (4) n.s. 
Glucagon 0.5 mg 4.26 i 0.63 (5) 3.28 f 0.22 (5) n.s. 
a Synthetic corticotropin-(l-24)-tetracosapeptide 
bP<O.O1 and 
’ P < 0.001 between hormone-treated and control rats 
Hormones were injected intraperitoneally (glucagon subcutaneously) into fed rats and liver 
samples taken 4 h later. Results are means f SEM from 4-7 experiments in each group 
(no. expts in parenthesis). n.s., not statistically significant 
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Table 2 
Effects of hormones on the activity of soluble phosphatidate phosphohydro~se in 
isolated perfused rat liver 
Perfusions Soluble phosphatidate phosphohydrolase 
activity (nmol. s-’ . g protein-‘) 
AtOh At4h Change 
Control 5 5.65 +_ 0.59 6.31 * 1.04 ns. 
Cortisol 5 5.42 f 0.39 14.85 -I 1.65 274%a 
Actinomycin D 4 6.40 + 0.97 4.94 + 0.41 n.s. 
Actinomycm D 
+ cortisol 4 5.12 + 0.44 4.14 r 0.56 n.s. 
Insulin 5 5.92 + 0.93 7.18 * 0.80 ns. 
a P .OO 1between < 0 the values at 0 h and 4 h 
Livers were perfused with hemoglobin-free perfusion medium (Eagle’s minimum essential 
medium) for 4 h, samples being taken at the beginning and end. Results are means i SEM 
from 4-5 perfusions in each group. n.s., not statistically significant 
adm~istration in vivo (5 mglkg body wt) increased hydrolase activity is increased by maternal cortico- 
the activity of the soiuble phosphatidate phospho- steroid administration, the hepatic activity of this 
hydrolase by 88% (P < 0.01) (table 1). enzyme decreases [17]. 
The effect of cortisol was also tested in perfused 
liver (table 2), the intention being to verify whether 
the in vivo results had been due to a direct effect 
upon the liver. Cortisol increased the activity of 
hepatic phosphatidate phosphohydrolase by 274% 
(P < 0 .OO l), but insulin had no statistically significant 
effect as compared with the control perfusions. Addi- 
tion of actinomycin D to the perfusion medium 
prevented the cortisol-induced increase in phospha- 
tidate phosphohydrolase activity. These results 
suggest hat the increased activity was due to an 
enhanced synthesis of enzyme protein. 
Thyroxine does not change the hepatic phospha- 
tidate phosphohydrolase within 4 h after administra- 
tion (table l), although a 2Sfold increase is observed 
when the injections are continued for 1 week [ 18 1. 
This indicates that the effects of thyroxine on phos- 
phatidate phosphohydrolase follow the pattern set 
by other effects of the thyroid hormones on metab- 
olism, which usually take several days 1191. This 
effect is interesting, in that it does not result in triacyl- 
glycerol accumulation [ 181, although hepatic neutral 
glycerolipid synthesis does increase in vitro [20]. 
Only recently, other evidence has been obtained 
on the hormonal regulation of phosphatidate phos- 
phohydrolase. It was demonstrated [l S] that nor- 
adrenaline rapidly reduces the activity of the 
Mg2*-dependent phosphatidate phosphohydrolase in 
adipocytes and insulin rapidly restores this activity 
[ 161. The results presented in table 2, however, 
demonstrate that the hormonal regulation of triacyl- 
glycerol synthesis may differ in principle in the liver, 
as it is not affected by insulin. In addition to this 
tissue-specific difference in the hormone-mediated 
regulation, the enzyme also shows developmental 
changes in its regulatory properties, viz. under condi- 
tions in which foetal lung phosphatidate phospho- 
It has been demonstrated that dibutyryl cyclic 
AMP stimulates the activity of the microsomal phos- 
phatidate phosphohydrolase [2 11. In the present 
study glucagon did not affect the activity of the 
soluble phosphatidate phosphohydrola~ in viva, 
although it is known to increase the hepatic concen- 
tration of cyclic AMP. 
Increased hepatic phosphatidate phosphohydrolase 
activity has been observed after sub-total hepatectomy 
[22], lap~otomy [ 221, fasting [23,24], a carbohydrate- 
rich diet 1251, induction of diabetes by streptozotocin 
[26] administration of ethanol [ 1,2,27,28], glycerol 
[ 18,271, sorbitol [ 18,271, fructose [27] or dihydroxy- 
acetone [IS]. Partial hepatectomy [29], laparotomy 
f29] and ethanol loading [7] are reported to result in 
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increased plasma corticosteroid concentrations, and 
the increase in the phosphatidate phosphohydrolase 
activity after the partial hepatectomy can be blocked 
by actinomycin D [22]. 
Glucocorticoids stimulate the synthesis of triacyl- 
glycerol in liver [30,3 11, but the mechanism is not 
known. Phosphatidate phosphohydrolase appears to 
have an important role in the regulation of neutral 
glycerolipid synthesis in liver [32,33]. It responds 
rapidly and dramatically to changes in the physiological 
and pharmacological status of animals [ 1,2,18,22-281 
and parallels the capacity of the liver to synthesize 
triacylglycerols [ 1,341. The present results demon- 
strate that cortisol has a direct increasing effect on 
the activity of hepatic phosphatidate phospho- 
hydrolase, a phenomenon also observable in an isolated 
perfused liver. The results thus lend support to the 
hypothesis that under most of the above-mentioned 
conditions adrenocortical steroids may be the medi- 
ators of the effects on phosphatidate phospho- 
hydrolase. This may have some bearing on the 
enhanced synthesis of hepatic triacylglycerols in 
certain stress states (e.g., ethanol loading, partial 
hepatectomy, laparotomy) and presumably also in 
obesity, at least in genetically obese mice, in which 
there is hyperfunction of the adrenal cortex [35] 
and increased activity of phosphatidate phospho- 
hydrolase [32]. 
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